GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Maternus-Kliniken AG (XTER:MAK) » Definitions » Research & Development

Maternus-Kliniken AG (XTER:MAK) Research & Development : €0.0 Mil (TTM As of Jun. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Maternus-Kliniken AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Maternus-Kliniken AG's Research & Development for the six months ended in Jun. 2023 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was €0.0 Mil.

Maternus-Kliniken AG Research & Development Historical Data

The historical data trend for Maternus-Kliniken AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maternus-Kliniken AG Research & Development Chart

Maternus-Kliniken AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Maternus-Kliniken AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Maternus-Kliniken AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maternus-Kliniken AG  (XTER:MAK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Maternus-Kliniken AG Research & Development Related Terms

Thank you for viewing the detailed overview of Maternus-Kliniken AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Maternus-Kliniken AG (XTER:MAK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Maternus-Kliniken AG (XTER:MAK) » Definitions » Research & Development
Comparable Companies
FRA:EIF XTER:V3V HCA SAU:4013 SZSE:300015 XTER:FRE BKK:BDMS ADX:PUREHEALTH XTER:FME DVA XKLS:5225 HKSE:06618 BSP:RDOR3 UHS NSE:APOLLOHOSP THC BOM:543220 CHE EHC ASX:RHC
Traded in Other Exchanges
MAK:Germany MAK:Germany MAK:Germany
Address
Strasse 53 - 55, Berlin, DEU, 10117
Website
https://www.maternus.de
Maternus -Kliniken AG operates as a German Health Care company focussed on senior housing, care facilities and rehabilitaion clincs. The company has became part of the CURA entrepreneurial group in 2007.

Maternus-Kliniken AG (XTER:MAK) Headlines

No Headlines